Navigation Links
Mirixa Debuts New Clinical Technology Solutions for Enhancing Patient Care

MirixaPro 2.2 enables the next generation in medication therapy management

and medication adherence services

RESTON, Va., Sept. 17 /PRNewswire/ -- Mirixa Corporation, a leading developer of innovative clinical solutions that facilitate pharmacist-based patient care services, today announced the immediate availability of version 2.2 of the MirixaPro(TM) product suite (MirixaPro 2.2). With this latest release of MirixaPro, pharmacies nationwide have fingertip access to an enhanced array of clinical care management tools that streamline pharmacy-based delivery of targeted patient care services including medication therapy management (MTM), medication adherence and disease management.

Leveraging Mirixa's technology, pharmacists have delivered tens of thousands of targeted MTM patient interventions, resolved thousands of alerts indicating potential safety issues and worked actively with patients and physicians to improve medication-related care. Qualifying patient cases are delivered directly and securely to the pharmacist, along with the patient's medication history. MirixaPro's workflow system supports delivery of multiple interventions through a single Web-based interface.

"Medication non-adherence and inadequate medication management is nothing short of a national epidemic," says Eric Zimmerman, Chief Innovation Officer and General Manager of Mirixa Clinical. "About 50% of patients with chronic conditions do not take their medications correctly -- we can and must do far better. At Mirixa, we're convinced the solution starts by levering the 'triangle of trust' between patients, physicians and pharmacists.

"MirixaPro makes collaboration easier by using data to pinpoint care improvement opportunities, monitor progress, and speed the flow of information across a secure network of care. The results so far are encouraging -- every day we hear from pharmacists using our technologies to collaborate with physicians to close gaps in care, resolve safety risks, and help consumers become confident and successful in managing their health," added Zimmerman.

MirixaPro 2.2 will be previewed by industry leaders at the Health 2.0 Conference on September 20 in San Francisco, CA as well as at the NACDS Medication Therapy Management Services in Community Pharmacy Conference September 19-20 in Philadelphia, PA.

About Mirixa

Mirixa Corporation is a leading developer of innovative clinical solutions that facilitate pharmacist-based patient care services and a leader in Medication Therapy Management (MTM) technology solutions. Founded by the National Community Pharmacists Association (NCPA), Mirixa has assembled the largest pharmacy services network of its kind with over 40,000 contracted community pharmacies -- including both independents and chains. Mirixa's technology portfolio empowers the delivery of highly targeted medication management programs, patient education, recruitment campaigns and patient medication records. The company's leadership team shares a vision and passion for improving patient care, reducing overall health costs, and expanding consumer access to accurate medication information. Mirixa is headquartered in the heart of the Dulles Technology Corridor in Reston, VA; with offices in California, Texas and New Jersey. For more information visit

Contact: Liz Deakin

Mirixa Corporation

Phone: 703-600-1226


SOURCE Mirixa Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. How do patients benefit of clinical trials
2. Magnetic resonance angiography in clinical medicine
3. Clinical trials need to be more frank
4. AEternas acquisition of Zentaris being followed up with its new product pipeline and clinical development strategy
5. Physicians Lack Clinical Guidelines For Treating Elderly With Multiple Illnesses
6. The Growing Rise In Clinical Research Could Lead To A Compromise In Quality Of Research And Ethics
7. Clinical Comparisons Between ADHD Drugs Are Less
8. Outsourcing clinical trials to India
9. Erectile dysfunction: an early warning sign of clinically silent coronary artery disease?
10. India to maintain Public domain Registry database of clinical trials conducted in India.
11. A Novel System For Clinical Banking Of Umbilical Cord Blood
Post Your Comments:
(Date:11/26/2015)... ... November 26, 2015 , ... WorldCare International, Inc., ... the 61st annual Employee Benefits Conference. The Employee Benefits Conference was hosted by ... through Wednesday, November 11th, 2015. The conference was held at the Hawaii Convention ...
(Date:11/26/2015)... ... November 26, 2015 , ... Indosoft Inc., developer and distributor of ... server to improve system efficiency and reliability. , The new Q-Suite 6 platform is ... the system avoids locking itself into a specific piece of software for many key ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... preparing the perfect dish and pleasing the palates of attendees is of the ... a dish to a seasonal get-together, give these recipes a try this holiday ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... offering factory direct sauna parts and accessories. , Sauna accessories help improve the ... bather’s style and personality. From basic styles for the purist looking for simplicity ...
(Date:11/25/2015)... ... ... On November 10, 2015, Bohrer Brady, LLC filed a class and collective ... home health care worker who provided companionship services for the elderly, ill or disabled ... Humana, Inc., Humana at Home, Inc., and SeniorBridge Family Companies (CT), Inc. since January ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 2015  Amgen (NASDAQ: AMGN ) today announced ... the United States (U.S.) Food ... candidate to Humira ® (adalimumab). Amgen believes this ... the FDA and represents Amgen,s first BLA submission using ... , M.D., executive vice president of Research and Development ...
(Date:11/25/2015)... -- On Tuesday, November 24, 2015, the jury ... Medical Technology, Inc. for product liability and misrepresentation ... device, awarded $11 million in favor of Plaintiff ... three days of deliberations, the jury found that ... and unreasonably dangerous, and that Wright Medical made ...
(Date:11/25/2015)... Nov. 25, 2015 Allergan plc (NYSE: AGN ... the New York State Attorney General,s ... Sherman Act, and other statutes with the Attorney General over ... to cease marketing and selling the now generic version of ... admits no liability, has released its counterclaims against ...
Breaking Medicine Technology: